Antiviral activity of a selective ribonucleotide reductase inhibitor against acyclovir-resistant herpes simplex virus type 1 in vivo

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 7, 1998, Pages 1629-1635

  Duan, Jianmin ^a   Liuzzi, Michel ^a   Paris, William ^a   Lambert, Michelle ^a   Lawetz, Carol ^a   Moss, Neil ^a   Jaramillo, Jorge ^a   Gauthier, Jean ^a   Déziel, Robert ^a   Cordingley, Michael G ^a  

^a BOEHRINGER INGELHEIM CANADA LTD   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; BILD 1633SE; CREMOPHOR; DIMETHYL SULFOXIDE; DNA POLYMERASE; DRUG VEHICLE; LINOLEIC ACID; OXIDOREDUCTASE INHIBITOR; RIBONUCLEOTIDE REDUCTASE; THYMIDINE KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CELL STRAIN BHK; CONTROLLED STUDY; CREAM; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SELECTIVITY; FEMALE; HERPES SIMPLEX VIRUS 1; HERPES VIRUS INFECTION; NONHUMAN; NUDE MOUSE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TOPICAL DRUG ADMINISTRATION; VIRUS ISOLATION;

EID: 0031862252     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.7.1629     Document Type: Article

References (42)

1. Bollinger, J. M., Jr., D. E. Edmondson, B. H. Huynh, J. Filley, J. R. Norton, and J. Stubbe. 1991. Mechanism of assembly of the tyrosyl radical-dinuclear iron cluster cofactor of ribonucleotide reductase. Science 253:292-298.
2. Bonneau, A.-M., P. Kibler, P. White, C. Bousquet, N. Dansereau, and M. G. Cordingley. 1996. Resistance of herpes simplex virus type 1 to peptidomimetic ribonucleotide reductase inhibitors: selection and characterization of mutant isolates. J. Virol. 70:787-793.
3. Brandt, C. R., R. L. Kintner, A. M. Pumfery, R. J. Visalli, and D. R. Grau. 1991. The herpes simplex virus ribonucleotide reductase is required for ocular virulence. J. Gen. Virol. 72:2043-2049.
4. Brandt, C. R., B. Spencer, P. Imesch, M. Garneau, and R. Deziel. 1996. Evaluation of a peptidomimetic ribonucleotide reductase inhibitor with a murine model of herpes simplex virus type 1 ocular disease. Antimicrob. Agents Chemother. 40:1078-1084.
5. Brazeau, P., N. Ling, P. Bohlen, F. Esch, S.-Y. Ying, and R. Guillemin. 1982. Growth hormone releasing factor, somatocrinin, releases pituitary growth hormone in vitro. Proc. Natl. Acad. Sci. USA 79:7909-7913.
6. Bridges, C. G., S. P. Ahmed, P. S. Sunkara, J. R. McCarthy, and A. S. Tyms. 1995. The ribonucleotide reductase inhibitor (E)-2′-fluoromethylene-2′-deoxycytidine (MDL 101,731): a potential topical therapy for herpes simplex virus infection. Antivir. Res. 27:325-334.
7. Chatis, P. A., and C. S. Crumpacker. 1992. Resistance of herpesviruses to antiviral drugs. Antimicrob. Agents Chemother. 36:1589-1595.
8. Coen, D. M. 1991. The implications of resistance to antiviral agents for herpesvirus drug targets and drug therapy. Antivir. Res. 15:287-300.
9. Coen, D. M., D. P. Aschman, P. T. Gelep, M. J. Retondo, S. K. Weller, and P. A. Schaffer. 1984. Fine mapping and molecular cloning of mutations in the herpes simplex virus DNA polymerase locus. J. Virol. 49:236-247.
10. Coen, D. M., D. J. Goldstein, and S. K. Weller. 1989. Herpes simplex virus ribonucleotide reductase mutants are hypersensitive to acyclovir. Antimicrob. Agents Chemother. 33:1395-1399.
11. Coen, D. M., M. Kosz-Vnenchak, J. G. Jacobson, D. A. Leib, C. L. Bogard, P. A. Schaffer, K. L. Tyler, and D. M. Knipe. 1989. Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate. Proc. Natl. Acad. Sci. USA 86:4736-4740.
12. Denizot, F., and R. Lang. 1986. Rapid colorimetric assay for cell growth and survival. J. Immunol. Methods 89:271-277.
13. Dutia, B. M., M. C. Frame, J. H. Subak-Sharpe, W. N. Clark, and H. S. Marsden. 1986. Specific inhibition of herpesvirus ribonucleotide reductase by synthetic peptides. Nature 321:439-443.
14. Ellis, M. N., D. C. Lobe, and T. Spector. 1989. Synergistic therapy by acyclovir and A1110U for mice orofacially infected with herpes simplex viruses. Antimicrob. Agents Chemother. 33:1691-1696.
15. Ellis, M. N., R. Waters, E. L. Hill, D. C. Lobe, D. W. Selleseth, and D. W. Barry. 1989. Orofacial infection of athymic mice with defined mixtures of acyclovir-susceptible and acyclovir-rcsistant herpes simplex virus type 1. Antimicrob. Agents Chemother. 33:304-310.
16. Furman, P. A., D. M. Coen, M. H. St. Clair, and P. A. Schaffer. 1981. Acyclovir-resistant mutants of herpes simplex virus type 1 express altered DNA polymerase or reduced acyclovir phosphorylating activities. J. Virol. 40:936-941.
17. Gaudreau, P., H. Paradis, Y. Langelier, and P. Brazeau. 1990. Synthesis and inhibitory potency of peptides corresponding to the subunit 2 C-terminal region of herpes virus ribonucleotide reductases. J. Med. Chem. 33:723-730.
18. Goldstein, D. J., and S. K. Weller. 1988. Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant. Virology 166:41-51.
19. Hall, J. D., P. A. Furman, M. H. St. Clair, and C. W. Knopf. 1985. Reduced in vivo mutagenesis by herpes simplex DNA polymerase involves improved nucleotide selection. Proc. Natl. Acad. Sci. USA 82:3889-3893.
20. Idowu, A. D., E. B. Fraser-Smith, K. L. Poffenberger, and R. C. Herman. 1992. Deletion of the herpes simplex virus type 1 ribonucleotide reductase gene alters virulence and latency in vivo. Antivir. Res. 17:145-156.
21. Jacobson, J. G., D. A. Leib, D. J. Goldstein, C. L. Bogard, P. A. S. Chaffer, S. K. Weller, and D. M. Coen. 1989. A herpes simplex virus ribonucleolide reductase deletion mutant is defective for productive acute and reactivatable latent infections of mice and for replication in mouse cells. Virology 173: 276-283.
22. Kimberlin, D. W., D. M. Coen, K. K. Biron, J. I. Cohen, R. A. Lamb, M. McKinlay, E. A. Emini, and R. J. Whitley. 1995. Molecular mechanisms of antiviral resistance. Antivir. Res. 26:369-401.
23. Kimberlin, D. W., C. S. Crumpacker, S. E. Straus, K. K. Biron, W. L. Drew, F. G. Hayden, M. McKinlay, D. D. Richman, and R. J. Whitley. 1995. Antiviral resistance in clinical practice. Antivir. Res. 26:423-438.
24. Krogsrud, R. L., E. Welchner, E. Scouten, and M. Liuzzi. 1993. A solid-phase assay for the binding of peptidic subunit association inhibitors to the herpes simplex virus ribonucleotide reductase large subunit. Anal. Biochem. 213: 386-394.
25. Laufer, D. S., and S. E. Starr. 1995. Resistance to antivirals. Pediatric Clin. N. Am. 42:583-599.
26. Liuzzi, M., and R. Déziel. 1993. Inactivation of herpes simplex virus ribonucleotide reductase by subunit association inhibitors: a potential antiviral strategy, p. 225-238. In J. Adams and V. J. Merluzzi (ed.), The search for antiviral drugs. Birkhauser, Boston, Mass.
27. Liuzzi, M., R. Déziel, N. Moss, P. Beaulieu, A.-M. Bonneau, C. Bousquet, J. G. Chafouleas, M. Garneau, J. Jaramillo, R. L. Krogsrud, L. Lagacé, R. S. McCollum, S. Nawoot, and Y. Guindon. 1994. A potent peptidomimetic inhibitor of HSV ribonucleotide reductase with antiviral activity in vivo. Nature 372:695-698.
28. Lobe, D. C., T. Spector, and M. N. Ellis. 1991. Synergistic topical therapy by acyclovir and A1110U for herpes simplex virus induced zosteriform rash in mice. Antivir. Res. 15:87-100.
29. McClements, W., G. Yamanaka, V. Garsky, H. Perry, S. Bacchetti, R. Colonno, and R. B. Stein. 1988. Oligopeptides inhibit the ribonucleotide reductase of herpes simplex virus by causing subunit separation. Virology 162:270-273.
30. Moss, N., P. Beaulieu, J.-S. Duceppe, J.-M. Ferland, M. Garneau, J. Gauthier, E. Ghiro, S. Goulet, I. Guse, J. Jaramillo, M. Llinas-Brunet, E. Malenfant, R. Plante, M. Poirier, F. Soucy, D. Wernic, C. Yoakim, and R. Déziel. 1996. Peptidomimetic inhibitors of herpes simplex virus ribonucleotide reductase with improved in vivo antiviral activity. J. Med. Chem. 39:4173-4180.
31. Nordlund, P., B.-M. Sjoberg, and H. Eklund. 1990. Three-dimensional structure of the free radical protein of ribonucleotide reductase. Nature 345:593-598.
32. Paradis H., P. Gaudreau, P. Brazeau, and Y. Langelier. 1988. Mechanism of inhibition of herpes simplex virus (HSV) ribonucleotide reductase by a nonapeptide corresponding to the carboxyl terminus of its subunit 2. J. Biol. Chem. 263:16045-16050.
33. Pelosi, E., K. A. Hicks, S. L. Sacks, and D. M. Coen. 1992. Heterogeneity of a herpes simplex virus clinical isolate exhibiting resistance to acyclovir and foscarnet. Adv. Exp. Med. Biol. 312:151-158.
34. Pottage, J. C., Jr., and H. A. Kessler. 1995. Herpes simplex virus resistance to acyclovir: clinical relevance. Infect. Agents Dis. 4:115-124.
35. Reichard, P. 1988. Interactions between deoxyribonucleotide and DNA synthesis. Annu. Rev. Biochem. 57:349-374.
36. Spector, T., D. R. Averett, D. J. Nelson, C. U. Lamne, R. W. Morrison, Jr., M. H. St. Clair, and P. A. Furman. 1985. Potentiation of antiherpetic activity of acyclovir by ribonucleotide reductase inhibition. Proc. Natl. Acad. Sci. USA 82:4254-4257.
37. Spector, T., J. A. Harrington, and D. J. T. Porter. 1991. Herpes and human ribonucleotide reductases. Inhibition by 2-acetylpyridine 5-[(2-chloroanilino)-thiocarbonyl] thiocarbonohydrazone (348U87). Biochem. Phamacol. 42:91-96.
38. Spector, T., J. A. Harrington, R. Morrison, Jr., C. U. Lambe, D. J. Nelson, D. R. Averett, K. Biron, and P. A. Furman. 1989. 2-Acetylpyridine 5-[(dimethylamino)thiocarbonyl]-thiocarbonohydrazone (A1110U), a potent mactivator of ribonucleotide reductases of herpes simplex and varicella zoster viruses and a potentiator of acyclovir. Proc. Natl. Acad. Sci. USA 86:1051-1055.
39. Spector, T., D. C. Lobe, M. N. Ellis, T. A. Blumenkopf, and G. M. Szczech. 1992. Inactivators of the herpes simplex virus ribonucleotide reductase: hemotological profiles and in vivo potentiation of the antiviral activity of acyclovir. Antimicrob. Agents Chemother. 36:934-937.
40. Suhnel, J. 1990. Evaluation of synergism or antagonism for the combined action of antiviral agents. Antivir. Res. 13:23-40.
41. Trybala, E., T. Bergstrom, B. Svennerholm, S. Jeansson, J. C. Glorioso, and S. Olofsson. 1994. Localization of a functional site on herpes simplex virus type 1 glycoprotein C involved in binding to cell surface hepran sulphate. J. Gen. Virol. 75:743-752.
42. Yamada, Y., H. Kimura, T. Morishima, T. Daikoku, K. Maeno, and Y. Nishiyama. 1991. The pathogenicity of ribonucleotide reductase-Null mutants of herpes simplex virus type 1 in mice. J. Infect. Dis. 164:1091-1097.